Placebo News and Research

RSS

Can ibuprofen improve drug-resistant tuberculosis treatment?

While ibuprofen reduced inflammatory markers in drug-resistant TB patients, it did not enhance treatment outcomes, indicating the need for further research.

3 Jul 2026

Scientists urge caution over psychedelics as ADHD treatment

In recent years, there has been growing interest among adults with ADHD in the practice of microdosing classic psychedelics such as psilocybin and LSD.

1 Jul 2026

Melatonin may safely reduce chronic musculoskeletal pain, study finds

A sleep supplement widely used to treat insomnia could help reduce reliance on some of the most common and potentially harmful pain medications, new research from the University of Sydney suggests.

30 Jun 2026

Monoclonal antibody shows promise for treating acute respiratory distress syndrome

Doctors have few options for patients who develop a life-threatening lung condition called acute respiratory distress syndrome, or ARDS.

30 Jun 2026

New trial shows oral therapy increases growth in children with achondroplasia

New findings from a trial conducted at Children's Hospital Colorado (Children's Colorado) and University of Colorado (CU) Anschutz School of Medicine demonstrate significantly increased growth rates in children with achondroplasia, the most common form of dwarfism.

30 Jun 2026

Analysis shows artificial sweeteners may harm adult metabolism function

Since the first introduction of saccharin, an array of artificial and other non-nutritive (i.e., low-calorie or calorie-free) sweeteners have become ubiquitous in the US food supply.

30 Jun 2026

Fiber blend relieves constipation and improves stool consistency

A recent study found that a combination of dietary fibers effectively alleviated chronic constipation, enhancing bowel function and stool quality in adults.

30 Jun 2026

Review assesses the efficacy of creatine as an add-on therapy for depression

Walk into any gym supplement aisle and creatine is there, sold by the tub to people chasing bigger muscles. It is one of the most studied compounds in sports science.

30 Jun 2026

Okra supplements may lower cholesterol and inflammation markers in diabetes

...

29 Jun 2026

Nasal viruses may drive allergic rhinitis, and ribavirin shows early promise as a targeted spray treatment

Nasal commensal viruses may worsen allergic rhinitis by activating type I IFN-linked neutrophils and NET formation. Ribavirin reduced nasal viral abundance and improved symptoms in mice and in a small phase 2 trial.

28 Jun 2026

Common drug shows promise in preventing post-surgical liver failure

A multi-center study, co-led by researchers at Mayo Clinic and Michigan State University, found that patients who received tranexamic acid during liver surgery were three times less likely to develop post-hepatectomy liver failure than patients who received a placebo.

25 Jun 2026

Exercise, not liraglutide alone, drives vascular gains after obesity-related weight loss

A prespecified secondary analysis of the S-LiTE trial found that regular exercise reduced carotid artery wall thickness and circulating levels of inflammatory cytokines in adults with obesity who had already achieved substantial diet-induced weight loss. Liraglutide alone did not significantly improve these vascular or inflammatory markers, while exercise plus liraglutide also improved endothelial function biomarkers.

25 Jun 2026

Spermidine supplement improves COVID 19 vaccine response in older adults

As we age, the immune system gradually declines and becomes less effective at responding to infections and vaccines.

25 Jun 2026

High-dose DHA reaches the brain but fails to protect memory

High-dose DHA effectively increased brain levels in older adults at Alzheimer's risk, but did not lead to cognitive or structural brain health improvements.

25 Jun 2026

New oral drug shows promise for chronic heart failure treatment

An early clinical study shows that a new oral drug is safe and well-tolerated in patients with chronic heart failure.

24 Jun 2026

Trial identifies 4 grams a day as the tested safe level for L-tyrosine in healthy men

A randomized, crossover trial in healthy adult men found that 4 weeks of L-tyrosine supplementation at doses up to 4 g/day did not cause clinically meaningful changes in safety markers, diet, blood pressure, or body measures. The highest tested dose, 4 g/day, was identified as the no-observed-adverse-effect level under the study’s four-week conditions, although broader and longer-term studies are still needed.

23 Jun 2026

New vaccines successfully boost frontline immune cells against HIV

T-cells are the immune system's frontline defenders with a crucial role in controlling HIV. In a milestone clinical trial published in the Journal of Clinical Investigation, researchers with the UNC Institute for Global Health and Infectious Diseases (IGHID) at the UNC School of Medicine have demonstrated that new vaccines can significantly boost T cells targeting the most vulnerable, conserved regions of HIV-areas considered key to effective immune control.

22 Jun 2026

Heart failure treatments protect heart function during cancer therapy

The cardioprotective effects of heart failure treatments in patients with cancer were demonstrated today in a presentation at ESC Cardio-Oncology 2026, the annual conference of the European Society of Cardiology's Council of Cardio-Oncology.

19 Jun 2026

Fish oil supplements show little benefit for Alzheimer's prevention

Americans spend more than $1 billion annually on fish oil supplements, in part due to purported cognitive benefits from the omega-3 fatty acids they contain, essential nutrients that help form brain cell connections needed for cognition.

18 Jun 2026

AI-designed drug for Parkinson's begins first human trial

Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced it has achieved the first clinical milestone in its co-development collaboration with Hygtia Therapeutics with the completion of first-in-human dosing in the Phase I study of ISM8969.

17 Jun 2026